definiens: means any Intelle ctual Property Rights existing or arising in [ * * ] including any Patent Rights filed in respect of the same by or on behalf of UCLB from time to time ; means any AAV -directed gene therapy that is not a Royalty Product and which incorpora tes within it the FX Vector other than where the vector includes [ * * ] ; means an academic, charitable or other not -for - profit organisation ( excluding any that is established in the [ * * ] or that is directly or indirectly under the control or direct ion of any such organisation ) including academic institutions, charities, and government bodies ; means, excluding the Additional Program Patents, any Patent Rights filed by or on behalf of UCLB from time to time that claim any of the appl icable Program Know -How ; means the treatment, prevention, cure, management, diagnosis and/or control of conditions concerning or related to [ * * ], including the condition referred to as ‘ [ * * ] ’, and associated symptoms ; has the meaning set out in Clause 2.4.4 ; means any Patent Rights filed by or on behalf of UCLB from time to time in respect of ( i ) the constructs identified under the [ * * ] Program including those identified in Part D of Schedule 2 ; and ( ii ) any Future Patents filed in respect of any of the Program Know -How identified in ( ii ) of [ * * ] Program IP ; means, excluding Additional Royalty Products, any AAV -directed gene therapy product which is indicated ( by way of its product label or package insert ) for use in the [ * * ] Field and is Covered by any of the [ * * ] Program IP, Manufacturing Know -How, Serotype IP and/or Promoter Program IP licensed to Liverco hereunder ; means the program of research defined in Schedule 1 under the title ; means ( i ) [ * * ] Patent Rights ; and ( ii ) Program Know -How applicable to Exploitation within the [ * * ] Field ; has the meaning set out in Clause 2.4.8 ; means any Patent Rights fi led by or on behalf of UCLB from time to time in respect of ( i ) any work undertaken by AN and/or the AN Laboratory prior to, on or after the Effective Date under or pursuant to the [ * * ] Program as set out in Schedule 1, but excluding the [ * * ] ; and ( ii ) any Program Know -How identified in ( ii ) of [ * * ] IP ; 11 Certain confidential information contained in this document, marked by [ * * ], has been omitted because the information ( i ) is not material and ( ii ) would likely cause competitive harm to the Compan y if publicly disclosed